Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aldoxorubicin: Phase IIb ongoing

CytRx said a data safety monitoring committee recommended continuation of an open-label, international Phase IIb trial comparing aldoxorubicin vs.

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE